2, 4 -diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation

Details for Australian Patent Application No. 2010251943 (hide)

Owner Boehringer Ingelheim International GmbH

Inventors Sapountzis, Ioannis; Stadtmueller, Heinz; Kuhn, Daniel

Agent Spruson & Ferguson

Pub. Number AU-A-2010251943

PCT Pub. Number WO2010/136559

Priority 09161496.6 29.05.09 EP; 10161628.2 30.04.10 EP

Filing date 28 May 2010

Wipo publication date 2 December 2010

International Classifications

C07D 239/48 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

A61K 31/505 (2006.01) - Pyrimidines

A61P 35/00 (2006.01) Antineoplastic agents

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

Event Publications

1 December 2011 PCT application entered the National Phase

  PCT publication WO2010/136559 Priority application(s): WO2010/136559

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010251948-Substituted aminobutyric derivatives as neprilysin inhibitors

2010251930-3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors